Company intelligence / Profile preview

MediVector

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

MediVector primarily focused on the development of favipiravir (T-705) for serious viral infections. The company reached Phase 3 clinical trials for Ebola virus disease in partnership with the US Department of Defense. However, development stalled due to legal disputes and the termination of government contracts.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Toyama ChemicalFujifilmUnited States Department of Defense (DoD)Biomedical Advanced Research and Development Authority (BARDA)

Beyond the preview

Go deeper on MediVector.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MediVector.

Explore the full profile